The puzzle of nitrate tolerance: Pieces smaller than we thought?

Circulation

Volumn 106, Issue 18, 2002, Pages 2404-2408

  Gori, Tommaso ^a   Parker, John D ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Acetylcholine; Blood flow; Endothelium; Nitric oxide synthase; Nitroglycerin

Indexed keywords

FREE RADICAL; GLYCERYL TRINITRATE; NEUROHORMONE; NITRATE; NITRIC OXIDE SYNTHASE; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

AUTONOMIC NERVOUS SYSTEM; DRUG TOLERANCE; ENDOTHELIUM; HORMONAL REGULATION; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; BLOOD VESSELS; CARDIOVASCULAR DISEASES; DRUG TOLERANCE; ENDOTHELIUM, VASCULAR; FREE RADICALS; HUMANS; NITRATES; NITROGLYCERIN; VASODILATOR AGENTS;

EID: 0037195062     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000036742.52907.91     Document Type: Short Survey

References (71)

1. Dufour P, Vinatier D, Puech F. The use of intravenous nitroglycerin for cervico-uterine relaxation: A review of the literature. Arch Gynecol Obstet. 1997;261:1-7.
2. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338:520-531.
3. Munzel T, Hink U, Yigit H, et al. Role of superoxide dismutase in in vivo and in vitro nitrate tolerance. Br J Pharmacol. 1999;127:1224-1230.
4. Munzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95:187-194.
5. Huie RE, Padmaja S. The reaction of NO with superoxide. Free Radic Res Commun. 1993;18:195-199.
6. Elliott SJ, Lacey DJ, Chilian WM, et al. Peroxynitrite is a contractile agonist of cerebral artery smooth muscle cells. Am J Physiol. 1998;275:H1585-H1591.
7. Skatchkov M, Larina LL, Larin AA, et al. Urinary nitrotyrosine content as a marker of peroxynitrite-induced tolerance to organic nitrates. J Cardiovasc Pharmacol Ther. 1997;2:85-96.
8. Dikalov S, Fink B, Skatchkov M, et al. Formation of reactive oxygen species in various vascular cells during glyceryltrinitrate metabolism. J Cardiovasc Pharmacol Ther. 1998;3:51-62.
9. Mihm MJ, Coyle CM, Jing L, et al. Vascular peroxynitrite formation during organic nitrate tolerance. J Pharmacol Exp Ther. 1999;291:194-198.
10. Bassenge E, Fink N, Skatchkov M, et al. Dietary supplement with vitamin C prevents nitrate tolerance. J Clin Invest. 1998;102:67-71.
11. Dikalov S, Fink B, Skatchkov M, et al. Comparison of glyceryl trinitrate-induced with pentaerythrityl tetranitrate-induced in vivo formation of superoxide radicals: Effect of vitamin C. Free Radic Biol Med. 1999;27:170-176.
12. Milone SD, Pace-Asciak CR, Reynaud D, et al. Biochemical, hemodynamic, and vascular evidence concerning the free radical hypothesis of nitrate tolerance. J Cardiovasc Pharmacol. 1999;33:685-690.
13. Munzel T, Kurz S, Heitzer T, et al. New insights into mechanisms underlying nitrate tolerance. Am J Cardiol. 1996;77:24C-30C.
14. Mollnau H, Wendt M, Szocs K, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/CGMP signaling. Circ Res. 2002;90:E58-E65.
15. Munzel T, Kurz S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: A new action for an old drug. J Clin Invest. 1996;98:1465-1470.
16. Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:1575-1580.
17. Laursen JB, Boesgaard S, Poulsen HE, et al. Nitrate tolerance impairs nitric oxide-mediated vasodilation in vivo. Cardiovasc Res. 1996;31:814-819.
18. Gori T, Mak SS, Kelly S, et al. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol. 2001;38:1096-1101.
19. Buga GM, Griscavage JM, Rogers NE, et al. Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res. 1993;73:808-812.
20. Chen LY, Mehta JL. Downregulation of nitric oxide synthase activity in human platelets by nitroglycerin and authentic nitric oxide. J Investig Med. 1997;45:69-74.
21. Caramori PR, Adelman AG, Azevedo ER, et al. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol, 1998;32:1969-1974.
22. Munzel T, Li H, Mollnau H, et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression. NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res. 2000;86:E7-E12.
23. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors. Proc Natl Acad Sci U S A. 1998;95:9220-9225.
24. Xia Y, Tsai AL, Berka V, et al. Superoxide generation from endothelial nitric-oxide synthase: A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem. 1998;273:25804-25808.
25. Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoE-deficient mice: Implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001;103:1282-1288.
26. Gruhn N, Aldershvile J, Boesgaard S. Tetrahydrobiopterin improves endothelium-dependent vasodilation in nitroglycerin-tolerant rats. Eur J Pharmacol. 2001;416:245-249.
27. Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2002;22:6-13.
28. Gori T, Burstein JM, Ahmed S, et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: A human in vivo study. Circulation. 2001;104:1119-1123.
29. Verhaar MC, Wever RM, Kastelein JJ, et al. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation. 1998;97:237-241.
30. Wilmink HW, Stroes ES, Erkelens WD, et al. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2000;20:185-188.
31. Loscalzo J. Folate and nitrate-induced endothelial dysfunction: A simple treatment for a complex pathobiology. Circulation. 2001;104:1086-1088.
32. Joshi R, Adhikari S, Patro BS, et al. Free radical scavenging behavior of folic acid: Evidence for possible antioxidant activity. Free Radic Biol Med. 2001;30:1390-1399.
33. Hyndman E, Verma S, Rosenfeld RJ, et al. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am J Physiol Heart Circ Physiol. 2002;282:H2167-H2172.
34. Abou-Mohamed G, Kaesemeyer WH, Caldwell RB, et al. Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin. Br J Pharmacol. 2000;130:211-218.
35. Kaesemeyer WH, Ogonowski AA, Jin L, et al. Endothelial nitric oxide synthase is a site of superoxide synthesis in endothelial cells treated with glyceryl trinitrate: Effects of NO donors and synthase agonists on endothelial cell uptake of L-Arg and superoxide production. Br J Pharmacol. 2000;131:1019-1023.
36. Ogonowski AA, Kaesemeyer WH, Jin L, et al. Effects of NO donors and synthase agonists on endothelial ceil uptake of L-Arg and superoxide production. Am J Physiol Cell Physiol. 2000;278:C136-C143.
37. McDonald KK, Zharikov S, Block ER, et al. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox". J Biol Chem. 1997;272:31213-31216.
38. Wallner S, Hermetter A, Mayer B, et al. The alpha-amino group of L-arginine mediates its antioxidant effect. Eur J Clin Invest. 2001;31:98-102.
39. Parker JO, Parker JD, Caldwell RW, et al. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. J Am Coll Cardiol. 2002;39:1199-1203.
40. Dupuis J, Lalonde G, Lemieux R, et al. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: Role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol. 1990;16:923-931.
41. Munzel T, Heitzer T, Kurz S, et al. Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease. J Am Coll Cardiol. 1996;27:297-303.
42. Parker JD, Parker JO. Effect of therapy with an angiotensin-converting enzyme inhibitor on hemodynamic and counterregulatory responses during continuous therapy with nitroglycerin. J Am Coll Cardiol. 1993;21:1445-1453.
43. Parker JD. Counterregulatory responses: Sustained-release isosorbide-5-mononitrate versus transdermal nitroglycerin. J Cardiovasc Pharmacol. 1996;28:631-638.
44. Hebert D, Lam JY. Nitroglycerin rebound associated with vascular, rather than platelet, hypersensitivity. J Am Coll Cardiol. 2000;36:2311-2316.
45. Watanabe H, Kakihana M, Ohtsuka S, et al. Efficacy and rebound phenomenon related to intermittent nitroglycerin therapy for the prevention of nitrate tolerance. Jpn Circ J. 1998;62:571-575.
46. Thadani U. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovasc Drugs Ther. 1997;10:735-742.
47. Ferratini M. Risk of rebound phenomenon during nitrate withdrawal. Int J Cardiol. 1994;45:89-96.
48. Kubo T, Urabe Y, Suzuki S, et al. Dissociation of vascular tolerance and plasma norepinephrine adjustment during long-term nitrate therapy in human coronary arteries. Intern Med. 1999;38:773-779.
49. Pueyo ME, Arnal JF, Rami J, et al. Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells. Am J Physiol. 1998;274:C214-C220.
50. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
51. Kurz S, Hink U, Nickenig G, et al. Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation. 1999;99:3181-3187.
52. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system. Circulation. 1999;99:2027-2033.
53. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
54. Harada K, Sugimoto K, Kawaguchi A, et al. Effect of angiotensin II on venodilator response to nitroglycerin. Clin Pharmacol Ther. 2001;69:130-136.
55. Berkenboom G, Fontaine D, Unger P, et al. Absence of nitrate tolerance after long-term treatment with ramipril: An endothelium-dependent mechanism. J Cardiovasc Pharmacol. 1999;34:547-553.
56. Munzel T, Bassenge E. Long-term angiotensin-converting enzyme inhibition with high-dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo. Circulation. 1996;93:2052-2058.
57. Kahler J, Ewert A, Weckmuller J, et al. Oxidative stress increases endothelin-1 synthesis in human coronary artery smooth muscle cells. J Cardiovasc Pharmacol. 2001;38:49-57.
58. Kahler J, Mendel S, Weckmuller J, et al. Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol. 2000;32:1429-1437.
59. Imai T, Hirata Y, Emori T, et al. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992;19:753-757.
60. Ratz JD, Fraser AB, Rees-Milton KJ, et al. Endothelin receptor antagonism does not prevent the development of in vivo glyceryl trinitrate tolerance in the rat. J Pharmacol Exp Ther. 2000;295:578-585.
61. Munzel T, Giaid A, Kurz S, et al. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci U S A. 1995;92:5244-5248.
62. Kurz S, Hink U, Nickenig G, et al. Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation. 1999;99:3181-3187.
63. Heitzer T, Wenzel U, Hink U, et al. Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: Evidence for an involvement of protein kinase C. Kidney Int. 1999;55:252-260.
64. Gopalakrishna R, Anderson WB. Ca2+- and phospholipid-independent activation of protein kinase C by selective oxidative modification of the regulatory domain. Proc Natl Acad Sci U S A. 1989;86:6758-6762.
65. Hirata K, Kuroda R, Sakoda T, et al. Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension. 1995;25:180-185.
66. Zierhut W, Ball HA. Prevention of vascular nitroglycerin tolerance by inhibition of protein kinase C. Br J Pharmacol. 1996;119:3-5.
67. Munzel T, Mollnau H, Hartmann M, et al. Effects of a nitrate-free interval on tolerance, vasoconstrictor sensitivity and vascular superoxide production. J Am Coll Cardiol. 2000;36:628-634.
68. Ma SX, Schmid PG Jr, Long JP. Noradrenergic mechanisms and the cardiovascular actions of nitroglycerin. Life Sci. 1994;55:1595-1603.
69. Zanzinger J, Bassenge E, Zanzinger J. Role of nitric oxide in the neural control of cardiovascular function: Nitrates in different vascular beds, nitrate tolerance, and interactions with endothelial function. Cardiovasc Res. 1999;43:639-649.
70. Zanzinger J, Czachurski J, Seller H. Impaired modulation of sympathetic excitability by nitric oxide after long-term administration of organic nitrates in pigs. Circulation. 1998;97:2352-2358.
71. Gori T, Floras JS, Parker JD. Nitroglycerin blunts the gain of the baroreceptor-heart rate reflex. J Am Coll Cardiol. In press.